We have located links that may give you full text access.
Early Net Ultrafiltration during Continuous Renal Replacement Therapy: Impact of Admission Diagnosis and Association with Mortality.
Blood Purification 2023 November 23
INTRODUCTION: Continuous Renal Replacement Therapy (CRRT) is common in the Intensive Care Unit (ICU) but a high Net ultrafiltration rate (UFNET) calculated with daily data may increase mortality. We aimed to study early UFNET practice using minute-by-minute CRRT machine recordings and to assess its association with admission diagnosis and mortality.
METHODS: We studied CRRT treatments in three adult ICUs over 7-years. We calculated early UFNET rates minute-by-minute and categorised UFNET into tertiles of mean UFNET in the first 72 hours and admission diagnosis. We applied Cox-proportional hazards modelling with censoring of patients who died within 72 hours.
RESULTS: We studied 1218 patients; 154,712 hours and 9,282,729 minutes of CRRT (5,702 circuits). Mean early UFNET was 1.52 (1.46 to 1.57) mL/kg/hr. Early UFNET tertiles were similar to previously reported values at 0.00-1.20 mL/kg/hr, 1.21 to 1.93mL/kg/hr and >1.93mL/kg/hr. UFNET values were similar whether evaluated at 24 or 72 hours or for the entire duration of CRRT. There was, however, significant variation in UFNET practice by admission diagnosis: higher in respiratory diseases (pneumonia P=0.01, other P<0.0001), and cardiovascular disease (P=0.005) but lower in cardiothoracic surgery (P=0.04), renal (P=0.0003) and toxicology-associated diagnoses (P=0.01). Higher UFNET was associated with an increased hazard of death, HR 1.24 (1.13 to 1.37), independent of admission diagnosis, weight, age, sex, presence of ESKD and severity of illness.
CONCLUSION: Early UFNET practice reflects known tertiles but varies significantly by admission diagnosis. Higher early UFNET is independently associated with mortality. Impacts of UFNET on mortality may vary by admission diagnosis. Further work is required to elucidate the nature and mechanisms responsible for this association.
METHODS: We studied CRRT treatments in three adult ICUs over 7-years. We calculated early UFNET rates minute-by-minute and categorised UFNET into tertiles of mean UFNET in the first 72 hours and admission diagnosis. We applied Cox-proportional hazards modelling with censoring of patients who died within 72 hours.
RESULTS: We studied 1218 patients; 154,712 hours and 9,282,729 minutes of CRRT (5,702 circuits). Mean early UFNET was 1.52 (1.46 to 1.57) mL/kg/hr. Early UFNET tertiles were similar to previously reported values at 0.00-1.20 mL/kg/hr, 1.21 to 1.93mL/kg/hr and >1.93mL/kg/hr. UFNET values were similar whether evaluated at 24 or 72 hours or for the entire duration of CRRT. There was, however, significant variation in UFNET practice by admission diagnosis: higher in respiratory diseases (pneumonia P=0.01, other P<0.0001), and cardiovascular disease (P=0.005) but lower in cardiothoracic surgery (P=0.04), renal (P=0.0003) and toxicology-associated diagnoses (P=0.01). Higher UFNET was associated with an increased hazard of death, HR 1.24 (1.13 to 1.37), independent of admission diagnosis, weight, age, sex, presence of ESKD and severity of illness.
CONCLUSION: Early UFNET practice reflects known tertiles but varies significantly by admission diagnosis. Higher early UFNET is independently associated with mortality. Impacts of UFNET on mortality may vary by admission diagnosis. Further work is required to elucidate the nature and mechanisms responsible for this association.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app